AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a new paper co-authored by two AgeX scientists that could lead to new insights into the fundamental mechanisms of aging and why super-centenarians not only live the longest, but also experience extraordinary healthspans; an extension of the healthy years of life that compresses morbidity to a very short period near the end of life. The paper, “Induced pluripotency and spontaneous reversal of cellular aging in supercentenarian donor cells,” is published online in the peer-reviewed scientific journal “Biochemical and Biophysical Research Communications” from Elsevier. The senior author is Dana Larocca, PhD, VP of Discovery Research at AgeX, and the first author is Jieun Lee, PhD, Scientist at AgeX.